Tempest Reports Third Quarter 2026 Financial Results and Provides Business Update
Exclusively licensed Senlang’s CD7-Targeted lentiviral in vivo CAR-T platform following initial Phas
Exclusively licensed Senlang’s CD7-Targeted lentiviral in vivo CAR-T platform following initial Phas